Equities research analysts forecast that MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) will post earnings of ($0.07) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for MaxCyte’s earnings. The business is scheduled to issue its next earnings results after the market closes on Monday, January 1st.
On average, analysts expect that MaxCyte will report full-year earnings of ($0.27) per share for the current financial year, with EPS estimates ranging from ($0.32) to ($0.23). For the next financial year, analysts anticipate that the firm will report earnings of ($0.28) per share, with EPS estimates ranging from ($0.36) to ($0.24). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover MaxCyte.
MaxCyte (NASDAQ:MXCT – Get Rating) last released its quarterly earnings results on Tuesday, March 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.05). MaxCyte had a negative return on equity of 11.11% and a negative net margin of 56.30%.
A hedge fund recently bought a new stake in MaxCyte stock. Nkcfo LLC acquired a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 13,000 shares of the company’s stock, valued at approximately $91,000. Hedge funds and other institutional investors own 54.86% of the company’s stock.
MaxCyte Company Profile (Get Rating)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
- Iridium Communications Stock is Ready to Return to Orbit
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.